THCV Treatment for Smokers
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age21-65
SponsorUniversity of California, Los Angeles
About this trial
This study will randomize 32 non-treatment-seeking individuals who smoke cigarettes daily into a randomized, crossover, double-blind, placebo-controlled study testing the safety, tolerability, and initial efficacy of Δ9-tetrahydrocannabivarin (Δ9-THCV).
Eligibility criteria
Qualifiers
Be between the ages of 21 and 65;
Smoke 10 or more combustible cigarettes per day;
Have fewer than 3 months of smoking abstinence in the past year;
Has self-reported ≥10 lifetime uses of cannabis products;
Disqualifiers
Have current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine;
Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any other psychotic disorder;
Have a score of 3 or greater on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening or anytime during study participation;
Have a positive urine screen for any substances, including cannabis
Trial design
Treatments tested in this trial
- Δ9-Tetrahydrocannabivarin (oral gummy)
- Matched Placebo (oral gummy)
Treatment groups
32 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University of California, Los Angeles
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov